Ipsen to Acquire Albireo for ~$952M

Share this


Ipsen to Acquire Albireo for ~$952M


  • Ipsen to acquire all outstanding shares of Albireo at $42.00/share for an initial consideration of ~$952M representing a premium of 104% over Albireo's 1mos. avg. price of $20.60 along with one CVR of $10.00/share upon the US FDA’s approval of Bylvay in the Biliary Atresia. The transaction is expected to close at the end of Q1’23
  • The acquisition will accelerate Ipsen’s rare disease portfolio & pipeline. Albireo’s Bylvay (IBATi) is currently in late-stage development for rare pediatric liver disorder BA & is being evaluated in the P-III study with expected results at the end of 2024
  • Bylvay was approved in the US & EU in patients aged ≥3 & ≥6mos. with PFIC. Ipsen will also acquire A3907, currently in development for cholestatic liver disease

Ref: Ipsen | Image: Albireo

Related News:- Ipsen Reports P-III (NAPOLI 3) Trial Results of Onivyde for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions